Ximelagatran reduces risk of VTE

By  

Inpharma, Vol. 1, Iss. 1375, 2003-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Ximelagatran, melagatran dosage in severe renal impairment

By  

Inpharma, Vol. 1, Iss. 1400, 2003-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Ximelagatran/Melagatran: A Review of its Use in the Prevention of Venous Thromboembolism in Orthopaedic Surgery

By Evans H.C.   Perry C.M.   Faulds D.  

Drugs, Vol. 64, Iss. 6, 2004-01 ,pp. : 649-678

Adis International

Access to resources Recommend Favorite

Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran

By Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 743-753

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral Ximelagatran: A Population Model Analysis

By Eriksson Ulf G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 7, 2003-01 ,pp. : 687-701

Adis International

Access to resources Recommend Favorite